CYP19A1 and breast carcinoma: During a phase II study comparing buparlisib with a placebo in combination with fulvestrant in postmenopausal HR+ and HER2− breast cancer advanced during or after aromatase inhibitor therapy, buparlisib improved the median PFS (progression free survival) from 5 to 6.9 months [16].